Kazia Therapeutics Annual Report 2021

62 Kazia Therapeutics Limited 62 Annual Report 2021 NOTE 31. EARNINGS PER SHARE Consolidated 2021 2020 $ $ Loss after income tax attributable to the owners of Kazia Therapeutics Limited (8,421,960) (12,467,466) Number Number Weighted average number of ordinary shares used in calculating basic earnings per share 117,674,543 73,053,514 Weighted average number of ordinary shares used in calculating diluted earnings per share 117,674,543 73,053,514 Cents Cents Basic earnings per share (7.16) (17.07) Diluted earnings per share (7.16) (17.07) 1,865,000 unlisted convertible notes with a face value of $464,000 and 4,446,500 unlisted options have been excluded from the above calculations as they were anti-dilutive. NOTE 32. SHARE-BASED PAYMENTS All of the options set out below have been issued to employees and directors under the ESOP. During the financial year an expense of $636,383 was recognised. 2021 Tranche Grant date Expiry date Exercise price Balance at the start of the year Granted Exercised Expired / lapsed on termination of employment Balance at the end of the year 1 16/11/2015 16/11/2020 $2.200 236,667 - - (236,667) - 2 05/09/2016 05/09/2021 $1.630 50,000 - - - 50,000 3 12/10/2016 17/10/2021 $1.560 62,000 - - - 62,000 4 31/10/2016 01/11/2021 $1.380 12,500 - - - 12,500 5 21/11/2016 23/11/2021 $1.380 50,000 - - - 50,000 6 07/08/2017 07/08/2022 $0.670 224,000 - (121,500) (15,500) 87,000 7 05/02/2018 05/02/2023 $0.780 440,000 - (120,000) - 320,000 8 04/01/2019 04/01/2024 $0.492 250,000 - (200,000) (12,500) 37,500 9 13/11/2019 04/01/2024 $0.492 1,200,000 - - - 1,200,000 10 13/01/2020 13/01/2025 $0.881 250,000 - - (50,000) 200,000 11 09/11/2020 13/01/2025 $1.132 - 1,200,000 - - 1,200,000 12 09/11/2020 13/01/2025 $0.881 - 800,000 - - 800,000 13 04/01/2021 04/01/2025 $1.690 - 200,000 - - 200,000 2,775,167 2,200,000 (441,500) (314,667) 4,219,000 Weighted average exercise price $0.797 $1.090 $0.620 $1.850 $0.826 No options were forfeited during the year. At the end of the period the following outstanding options were vested and exercisable: • Options in tranche 1 have expired during the year • Options in tranches 2 - 8 were vested and exercisable except for tranche 6 which was vested as to 53% • Options in tranche 9 were vested as to 1million of the 1.2million options on issue • Options in tranches 10-12 were 25% vested • Options in tranche 13 were unvested at year end The weighted average remaining contractual life of options outstanding at 30 June 2021 is 2.6 years.